Phenibut: The Definitive Guide

What is phenibut?

Phenibut, or β-phenyl-γ-aminobutyric acid, is a synthetic analogue of the inhibitory neurotransmitter GABA. Adding a phenyl group changes how the molecule behaves and allows central nervous system activity that ordinary dietary GABA should not be assumed to share. Reviews describe GABA-B receptor agonism and activity at the α2δ subunit of voltage-gated calcium channels, but detailed human pharmacokinetic and dose-response data remain limited. [1], [2]

Its classification changes with jurisdiction. It is a registered prescription medicine in countries including Latvia, while it is not an FDA-approved medicine and is not a lawful dietary ingredient in the United States. Australia placed it in Schedule 9, its prohibited-substance category. WHO pre-reviewed it in 2021 and kept it under surveillance rather than recommending international scheduling at that meeting. [3], [4], [5]

Those distinctions matter. A medicine dispensed under a national product authorization, an online powder with an unverifiable label and a U.S. product sold as a “supplement” are not the same regulatory or quality context. This guide reports named sources and does not turn any of them into a self-treatment plan.

Typical Phenibut Protocols

Do not average or extend these rows. The Latvian report enrolled adults already given a new prescription in routine practice. It did not compare Noofen with placebo or another treatment. The WHO number summarizes reported therapeutic use and does not provide the administration-level detail needed to reproduce a protocol. Neither source establishes a safe schedule for internet powder, HCl versus free-amino-acid material, recreational use or withdrawal treatment. [4], [6]

Prescription product

The Latvian study used a named 250 mg capsule. Its findings cannot verify the identity, purity or amount in an online product.

Duration

The observational course was three weeks. It does not answer long-term effectiveness, dependence incidence or what happens after repeated courses.

Withdrawal treatment Not a do-it-yourself protocol

Published reports describe clinician-managed baclofen, benzodiazepine or phenobarbital approaches. Case-specific substitutions are not dose-conversion rules for home use. [7], [8]

What forms and names appear on labels?

Names include phenibut, fenibut, phenyl-GABA, PhGABA, β-phenyl-γ-aminobutyric acid and brand names such as Noofen or Anvifen. Online sellers may distinguish phenibut hydrochloride from a free-amino-acid form. A different salt or label does not remove the central nervous system, dependence or withdrawal concerns.

In the United States, a “dietary supplement” panel is not evidence that phenibut legally belongs in a supplement. FDA states that phenibut does not fit a statutory dietary-ingredient category and that supplements declaring it as an ingredient are misbranded. FDA has issued warning letters and describes a 2023 permanent injunction involving products that contained phenibut HCl. [3]

There is no established RDA, adequate intake or tolerable upper intake level because phenibut is not a nutrient. Product purity and label accuracy cannot be inferred from powder colour, taste, seller reviews or a vendor certificate alone.

How should an existing product be stored?

Follow the authorized pharmacy label when phenibut is a prescribed medicine. For an unregulated product, seller storage claims do not solve uncertain identity or purity. Keep any psychoactive product sealed in its original labelled container, secured from children and other household members, and away from moisture. Do not transfer a white powder into an unlabelled jar or food container.

If medical assessment may be needed, preserve the package and lot information. Do not taste, smell or experimentally redose a suspect product to identify it. A damaged seal, missing label, unexpected appearance or unexplained strength difference is a reason not to use the material.

What is phenibut commonly used for?

In countries with registered medicines, phenibut has been prescribed for anxiety-related and neurologic indications under local product information. Online users often seek calm, sleep or social disinhibition. These are reasons for exposure, not a benefit conclusion. Western evidence does not establish an approved over-the-counter treatment for anxiety, insomnia, cognition or social performance. [1], [4]

The Latvian observational study is the most direct recent human effectiveness report used here. Scores improved during three weeks of prescribed Noofen, particularly for sleep disturbance, restlessness and anxiety, but there was no comparison group. The design cannot show how much change came from the medicine. [6]

An acute calming or sedating effect can also reinforce repeated use. Tolerance, rebound symptoms and withdrawal can turn the original goal into a cycle of using to relieve the effects of stopping. A perceived benefit therefore cannot be evaluated separately from frequency, escalation and off-day function.

What does the human evidence show?

The efficacy literature and the harm literature are not balanced. Modern controlled trials supporting self-treatment for anxiety, sleep, cognition or social confidence are absent. The 2025 Latvian report found a mean 14.8-point reduction on the ADNM-20 adjustment-disorder scale after three weeks among 90 completers, but the uncontrolled design cannot separate drug effect from natural recovery, expectation, other care or regression to the mean. The article reports that several authors were employees of the manufacturer or otherwise linked to the product. [6]

The stronger population-level signal is U.S. poison-center surveillance. During 2009–2019, 1,320 phenibut exposures were reported from all states and Washington, D.C.; 85.0% of calls came from health-care facilities. Reported effects included agitation in 30.4%, drowsiness or lethargy in 29.0%, tachycardia in 21.9%, confusion in 21.3% and coma in 6.2%. Major effects occurred in 12.6%, and three deaths were reported. Among single-agent exposures, 10.2% had major effects and one death was reported. [9]

Poison-center records also have limits: exposures were reported rather than laboratory-confirmed, some involved other substances, reporting is incomplete, and the database term changed during the study period. These constraints prevent an incidence estimate, but they do not erase the documented severe outcomes. [9]

What are the main risks and interactions?

Acute toxicity can move in opposite directions: sedation, impaired coordination and reduced consciousness can occur, while agitation, delirium and abnormal movements are also reported. Coma and respiratory depression are reasons to treat phenibut as a serious psychoactive exposure rather than a gentle calming supplement. [2], [9]

Alcohol, opioids, benzodiazepines, Z-drugs, gabapentin, pregabalin, baclofen, GHB/GBL and other sedatives can produce additive or unpredictable central nervous system depression. Stimulants do not reliably “cancel” impairment and can obscure how intoxicated someone is. Driving, swimming or operating equipment while impaired adds injury risk.

Call emergency services for trouble breathing, inability to wake, seizure, collapse, severe confusion, hallucinations with unsafe behaviour or extreme agitation. In the United States, Poison Control is available at 1-800-222-1222. In Canada, local poison-centre access varies by province; emergency services remain appropriate for severe symptoms.

Pregnancy and lactation safety data are inadequate. Kidney disease could matter because reports describe substantial urinary excretion, but human pharmacokinetic evidence is thin. A history of substance-use disorder, escalating use, use to relieve withdrawal, or access to multiple depressants raises the practical risk.

What is the legal and regulatory status?

United States: phenibut is not an FDA-approved drug and does not meet the dietary-ingredient definition. FDA describes products declaring it as a dietary ingredient as misbranded. Possession and lawful marketing are separate questions; state rules and enforcement can change. [3]

Canada: phenibut is not presented here as an authorized natural health product. Product authorization must be checked against Health Canada’s current databases rather than inferred from online availability.

Australia: the Therapeutic Goods Administration scheduling decision placed phenibut in Schedule 9, a prohibited-substance category, effective in 2018. [5]

International: WHO’s 2021 pre-review documented medical use, misuse and dependence concerns. The committee recommended continued surveillance at that stage rather than international control, which is not a declaration of safety. [4]

What happens when regular use stops?

Withdrawal is the central safety issue. A 2024 systematic review found only 15 eligible published cases, so its percentages describe a selected case literature rather than all users. All 15 had neurologic symptoms; insomnia, hallucinations and muscle abnormalities each appeared in 8 cases, and anxiety in 6. Average reported use was 13.6 g/day for 8.2 months, but averages do not define a threshold below which withdrawal cannot occur. [7]

Treatment in the reports varied. Nine cases used a baclofen taper and six used benzodiazepine-based approaches, often with other supportive or intensive-care treatment. An earlier single case described clinician-managed substitution with baclofen. It does not establish a validated conversion formula; attempting substitution without medical oversight could add baclofen toxicity or another withdrawal problem. [7], [8]

Do not use this page to design a taper. If use has become regular, amounts have escalated, or symptoms appear between doses, seek medical advice before an abrupt stop. Bring the exact product, labelled form, approximate amounts, timing and co-used substances. Emergency symptoms need emergency care.

What should be monitored?

The most useful monitoring is a factual pattern of exposure and harm, not a score that tries to optimize the effect.

• Record the labelled form, amount, time and source of each actual exposure.
• Record alcohol, sedatives, stimulants and prescription medicines used in the same period.
• Watch for frequency creep, escalating amounts, redosing after a delayed onset, using to feel normal, morning anxiety, rebound insomnia or failed attempts to stop.
• Note impaired balance, memory gaps, vomiting, unusual movements, confusion, severe sedation, agitation or hallucinations.
• Share the record directly with a clinician because routine urine drug screens do not detect phenibut. [7], [9]

What does community experience add?

Community reports often discuss delayed onset, rapid tolerance, rebound anxiety, sleep disruption, escalating frequency and difficult tapers. They are useful for identifying questions that formal research may miss, but they cannot estimate a safe dose or frequency. Product identity is uncertain, dramatic experiences are more likely to be posted, and concurrent substances are often incompletely reported.

No systematic community estimate was used in this guide. “Once weekly,” “only on special occasions” and similar internet rules have not been validated as safe. The clinical and poison-center evidence takes priority when a forum rule conflicts with a harm signal.

How does phenibut compare with nearby options?

Common questions

Is phenibut a dietary supplement?

Not under FDA’s U.S. interpretation. FDA says it does not meet the statutory definition of a dietary ingredient, and supplements declaring it are misbranded. [3]

Does a Latvian prescription study prove that online phenibut works?

No. It studied a named prescription capsule in selected patients, had no control group and included manufacturer-linked authors. It cannot verify an online product or establish causation. [6]

Can dependence happen only at very high amounts?

The published withdrawal review contains many high-amount cases, but a selected case-series average cannot establish a safe lower threshold. Frequency creep, using to relieve rebound symptoms and difficulty stopping are warning signs. [7]

Can I stop abruptly?

Abrupt stopping after regular use can cause severe symptoms. Seek individualized medical advice; use emergency care for seizure, hallucinations, severe agitation, collapse or breathing problems.

Will phenibut appear on a routine drug screen?

Usually not. The CDC report notes that no commercially available test was available and routine urine screens did not detect it, which makes direct disclosure important. [9]

Is baclofen an at-home antidote?

No. Baclofen is a prescription drug with its own overdose and withdrawal risks. Published phenibut substitutions are clinician-managed cases, not a universal conversion table. [7], [8]

Glossary

Plain explanations of the pharmacology, evidence and regulatory terms used in this guide.

GABA-B receptor

A metabotropic receptor involved in inhibitory nervous-system signalling and one target of phenibut and baclofen.

α2δ subunit

A component associated with voltage-gated calcium channels and a target shared by gabapentinoid medicines.

Physical dependence

Adaptation in which reducing or stopping a substance can produce withdrawal symptoms.

Withdrawal

Symptoms after reducing or stopping a substance to which the body has adapted.

Observational study

Research that observes care without randomly assigning a comparison; improvement can have several explanations.

Misbranded

A U.S. regulatory term indicating that a product’s labelling or marketing does not comply with applicable law.

How this guide was researched

Research began with current FDA, CDC, WHO and Australian regulatory records. It then checked the full 2025 Latvian observational article, the 2024 systematic review of withdrawal cases and the original dependence case. Exact denominators and source-specific schedules were retained, while internet schedules and unsupported “safe use” rules were excluded.

Explore the sources

Related guides

• GABA
• L-theanine
• Magnesium

Editorial note

This guide distinguishes a named prescription product from internet phenibut, treats poison-center reports as surveillance rather than incidence, and refuses to convert case-report treatment into an at-home taper. It was authored in English and translated into Canadian French from the same evidence record.